Ania Jastreboff, MD ’12 PhD

Ania Jastreboff, MD, PhD is an associate professor in medicine and pediatrics at Yale School of Medicine. Jastreboff is trained in both adult endocrinology and pediatric endocrinology, is an obesity medicine physician-scientist, and an international leader in research and clinical application of anti-obesity pharmacotherapeutics.

Jastreboff’s work has included working to develop Obesity Clinical Practice Guidelines (AACE/ACE 2016), serving on the board of directors for the American Board of Obesity Medicine, educating the next generation of obesity medicine physicians by teaching at national and international obesity treatment courses, and conducting cutting-edge clinical-translational obesity research. Jastreboff’s research includes large, multi-center clinical outcomes trials using novel anti-obesity pharmacotherapeutics and studies examining the neurobiology underlying obesity and mechanisms of anti-obesity medications (supported by the NIH/NIDDK).

Recently, Jastreboff has served as lead author for trials investigating potential novel nutrient-stimulated hormone-based therapies for obesity, including dual hormone receptor agonist tirzepatide (NEJM) a novel GIP/GLP-1 receptor agonist (Jastreboff, et al., NEJM, 2022) and triple hormone receptor agonist retatrutide (NEJM) a novel GIP/GLP-1/Glucagon receptor agonist (Jastreboff, et al., NEJM, 2023). Jastreboff thoughtfully advocates for compassionate care for patients with obesity and was recently interviewed by Oprah.